{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:27:37Z","timestamp":1786724857830,"version":"build-2736575974"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Type 2 diabetes mellitus (T2DM) and obesity are the archetypal components of cardiometabolic syndromes associated with heart failure (HF) with preserved or mildly reduced ejection fraction (HFpEF\/HFmrEF). The specific contribution of T2DM, independent of obesity, to myocardial adaptations and outcomes remains uncertain. We aimed to explore the obesity-independent contribution of T2DM to cardiac structure, function, central haemodynamics, and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We leveraged the sham-control arm of the REDUCE LAP-HF II trial (n = 312), a prospectively phenotyped cohort of patients with HFpEF\/HFmrEF undergoing invasive haemodynamic assessment. Multivariable models were used to adjust for body mass index (BMI) and clinical covariates. Outcomes included cardiovascular (CV) death and total HF events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>T2DM was present in 37% of patients and was associated with higher BMI, chronic kidney disease, and prior HF hospitalization. Obesity was present in 62% of patients and was more prevalent in those with T2DM (70% vs 57%, P = .032). After adjustment for BMI, T2DM remained independently associated with greater left ventricular mass, lower EF, impaired left ventricular global longitudinal strain, reduced right ventricular free-wall strain, and higher resting filling pressures. Over a median of 4.0-year (2.5\u20135.0) follow-up, T2DM was independently associated with increased risk of HF events or CV death (adjusted hazard ratio: 1.96, 95% confidence interval: 1.28\u20133.00), driven by HF events, whereas BMI was not independently prognostic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HFpEF\/HFmrEF patients with T2DM experience adverse myocardial remodelling, impaired biventricular function, adverse central haemodynamics, and worse clinical outcomes independent of obesity. These findings indicate that T2DM confers additional metabolic burden to the myocardium, beyond that attributable to obesity alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag210","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T11:55:09Z","timestamp":1786190109000},"source":"Crossref","is-referenced-by-count":0,"title":["Type 2 diabetes in heart failure with preserved and mildly reduced ejection fraction: insights from the REDUCE-LAP-HF II trial"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2353-9776","authenticated-orcid":false,"given":"Misha","family":"Dagan","sequence":"first","affiliation":[{"name":"Department of Cardiology, Alfred Hospital , 55 Commercial Rd, Melbourne, Victoria 3004 ,","place":["Australia"]},{"name":"Faculty of Medicine, Nursing and Health Sciences, Monash University , Clayton, Melbourne, Victoria 3800 ,","place":["Australia"]},{"name":"Heart Failure Research Group, Baker Heart and Diabetes Institute , 99 Commercial Rd, Melbourne, Victoria 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-6588","authenticated-orcid":false,"given":"Shane","family":"Nanayakkara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Alfred Hospital , 55 Commercial Rd, Melbourne, Victoria 3004 ,","place":["Australia"]},{"name":"Faculty of Medicine, Nursing and Health Sciences, Monash University , Clayton, Melbourne, Victoria 3800 ,","place":["Australia"]},{"name":"Monash-Alfred-Baker Centre for Cardiovascular Research, Monash University , Clayton, Melbourne, Victoria 3800 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3802-1961","authenticated-orcid":false,"given":"Anna L","family":"Beale","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Alfred Hospital , 55 Commercial Rd, Melbourne, Victoria 3004 ,","place":["Australia"]},{"name":"Monash-Alfred-Baker Centre for Cardiovascular Research, Monash University , Clayton, Melbourne, Victoria 3800 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Komtebedde","sequence":"additional","affiliation":[{"name":"Corvia Medical Inc. , Tewksbury, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Mylavarapu","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine , Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Hasenfu\u03b2","sequence":"additional","affiliation":[{"name":"Heart Center, University Medical Center , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon E","family":"Litwin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University of South Carolina , Charleston, SC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Mohan","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Advanced Heart Failure and Mechanical Circulatory Support Program, Pulmonary Hypertension Program , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M","family":"Gorter","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Centre Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4772-5549","authenticated-orcid":false,"given":"Maja","family":"Cikes","sequence":"additional","affiliation":[{"name":"Department for Cardiovascular Diseases, University Hospital Centre Zagreb, University of Zagreb School of Medicine , Zagreb ,","place":["Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald E","family":"Cutlip","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Baim Institute , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin B","family":"Leon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Columbia University Irving Medical Center\/NewYork Presbyterian Hospital , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5655-8201","authenticated-orcid":false,"given":"Sanjiv","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine , Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Kaye","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Alfred Hospital , 55 Commercial Rd, Melbourne, Victoria 3004 ,","place":["Australia"]},{"name":"Faculty of Medicine, Nursing and Health Sciences, Monash University , Clayton, Melbourne, Victoria 3800 ,","place":["Australia"]},{"name":"Heart Failure Research Group, Baker Heart and Diabetes Institute , 99 Commercial Rd, Melbourne, Victoria 3004 ,","place":["Australia"]},{"name":"Monash-Alfred-Baker Centre for Cardiovascular Research, Monash University , Clayton, Melbourne, Victoria 3800 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"2026081410521714900_xvag210-B1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s00125-023-06068-2","article-title":"Epidemiology of heart failure in diabetes: a disease in disguise","volume":"67","author":"Hoek","year":"2024","journal-title":"Diabetologia"},{"key":"2026081410521714900_xvag210-B2","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.123.011366","article-title":"Uncovering unrecognized heart failure with preserved ejection fraction among individuals with obesity and dyspnea","volume":"17","author":"Kosyakovsky","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026081410521714900_xvag210-B3","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/ejhf.3221","article-title":"Body mass index and cardiorenal outcomes in the EMPEROR-preserved trial: principal findings and meta-analysis with the DELIVER trial","volume":"26","author":"Sattar","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026081410521714900_xvag210-B4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"2026081410521714900_xvag210-B5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ejhf.3092","article-title":"Obesity in heart failure with preserved ejection fraction: insights from the REDUCE LAP-HF II trial","volume":"26","author":"Litwin","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026081410521714900_xvag210-B6","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/cir.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"2026081410521714900_xvag210-B7","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1007\/s00330-024-10658-y","article-title":"Long-term outcomes prediction in diabetic heart failure with preserved ejection fraction by cardiac MRI","volume":"34","author":"Yang","year":"2024","journal-title":"Eur Radiol"},{"key":"2026081410521714900_xvag210-B8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jchf.2019.01.006","article-title":"Central and peripheral determinants of exercise capacity in heart failure patients with preserved ejection fraction","volume":"7","author":"Wolsk","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026081410521714900_xvag210-B9","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.jacc.2025.03.530","article-title":"Disentangling the impact of adiposity from insulin resistance in heart failure with preserved ejection fraction","volume":"85","author":"Reddy","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026081410521714900_xvag210-B10","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jacc.2025.07.052","article-title":"Is type 2 diabetes a modifiable risk factor for the evolution and progression of heart failure with a preserved ejection fraction?","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026081410521714900_xvag210-B11","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction","volume":"86","author":"Packer","year":"2025","journal-title":"JACC"},{"key":"2026081410521714900_xvag210-B12","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.121.021584","article-title":"Comprehensive physiological modeling provides novel insights into heart failure with preserved ejection fraction physiology","volume":"10","author":"Kaye","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026081410521714900_xvag210-B13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jacbts.2023.11.006","article-title":"Cardiac substrate utilization and relationship to invasive exercise hemodynamic parameters in HFpEF","volume":"9","author":"O'Sullivan","year":"2024","journal-title":"JACC Basic Transl Sci"},{"key":"2026081410521714900_xvag210-B14","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s10741-025-10545-8","article-title":"Determinants of exercise tolerance in HFpEF: role of the heart versus the periphery","volume":"30","author":"Bergeron","year":"2025","journal-title":"Heart Fail Rev"},{"key":"2026081410521714900_xvag210-B15","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jacc.2025.06.058","article-title":"Influence of type 2 diabetes on the effects of tirzepatide in patients with heart failure and a preserved ejection fraction with obesity: a prespecified stratification-based analysis","volume":"86","author":"Packer","year":"2025","journal-title":"JACC"},{"key":"2026081410521714900_xvag210-B16","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2026081410521714900_xvag210-B17","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026081410521714900_xvag210-B18","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026081410521714900_xvag210-B19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jamacardio.2024.0520","article-title":"Atrial shunt device effects on cardiac structure and function in heart failure with preserved ejection fraction: the REDUCE LAP-HF II randomized clinical trial","volume":"9","author":"Patel","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026081410521714900_xvag210-B20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1161\/circulationaha.117.032094","article-title":"Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): a phase 2, randomized, sham-controlled trial","volume":"137","author":"Feldman","year":"2018","journal-title":"Circulation"},{"key":"2026081410521714900_xvag210-B21","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.116.003662","article-title":"One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction","volume":"9","author":"Kaye","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026081410521714900_xvag210-B22","author":"The Society for Cardiovascular Ultrasound Professionals"},{"key":"2026081410521714900_xvag210-B23","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/s0140-6736(22)00016-2","article-title":"Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial","volume":"399","author":"Shah","year":"2022","journal-title":"Lancet"},{"key":"2026081410521714900_xvag210-B24","doi-asserted-by":"publisher","first-page":"2042018819861593","DOI":"10.1177\/2042018819861593","article-title":"Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetes","volume":"10","author":"Gulsin","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2026081410521714900_xvag210-B25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.amjcard.2009.09.041","article-title":"Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus","volume":"105","author":"Aguilar","year":"2010","journal-title":"Am J Cardiol"},{"key":"2026081410521714900_xvag210-B26","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jacc.2014.05.030","article-title":"Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study","volume":"64","author":"Lindman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026081410521714900_xvag210-B27","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/circulationaha.116.024593","article-title":"Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-preserve trial (irbesartan in heart failure with preserved ejection fraction)","volume":"135","author":"Kristensen","year":"2017","journal-title":"Circulation"},{"key":"2026081410521714900_xvag210-B28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12933-024-02185-3","article-title":"Prevalence and prognostic significance of cardiac autonomic neuropathy in community-based people with type 2 diabetes: the Fremantle Diabetes Study Phase II","volume":"23","author":"Davis","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026081410521714900_xvag210-B29","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/ejhf.2432","article-title":"Cardiac autonomic neuropathy and risk of incident heart failure among adults with type 2 diabetes","volume":"24","author":"Kaze","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026081410521714900_xvag210-B30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12933-023-01835-2","article-title":"Association of complication of type 2 diabetes mellitus with hemodynamics and exercise capacity in patients with heart failure with preserved ejection fraction: a case-control study in individuals aged 65-80 years","volume":"22","author":"Sugita","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026081410521714900_xvag210-B31","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/dme.12431","article-title":"Type 2 diabetes mellitus and obesity in young adults: the extreme phenotype with early cardiovascular dysfunction","volume":"31","author":"Wilmot","year":"2014","journal-title":"Diabet Med"},{"key":"2026081410521714900_xvag210-B32","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.119.014542","article-title":"Longitudinal changes in cardiac structure and function in severe obesity: 11-year follow-up in the Utah Obesity Study","volume":"9","author":"Litwin","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026081410521714900_xvag210-B33","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat Med"},{"key":"2026081410521714900_xvag210-B34","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/ejhf.2947","article-title":"Global longitudinal strain predicts clinical outcomes in patients with heart failure with preserved ejection fraction","volume":"25","author":"Brann","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026081410521714900_xvag210-B35","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2017-000630","article-title":"Left ventricular longitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis","volume":"4","author":"Morris","year":"2017","journal-title":"Open Heart"},{"key":"2026081410521714900_xvag210-B36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1161\/circulationaha.115.015884","article-title":"Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"132","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"2026081410521714900_xvag210-B37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.amjcard.2017.11.040","article-title":"Diabetes mellitus and right ventricular dysfunction in heart failure with preserved ejection fraction","volume":"121","author":"Gorter","year":"2018","journal-title":"Am J Cardiol"},{"key":"2026081410521714900_xvag210-B38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4330\/wjc.v4.i4.90","article-title":"Role of advanced glycation end products in cardiovascular disease","volume":"4","author":"Hegab","year":"2012","journal-title":"World J Cardiol"},{"key":"2026081410521714900_xvag210-B39","doi-asserted-by":"publisher","first-page":"E227","DOI":"10.1210\/jc.2012-3277","article-title":"The relation of glucose metabolism to left ventricular mass and function and sympathetic nervous system activity in obese subjects with metabolic syndrome","volume":"98","author":"Straznicky","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026081410521714900_xvag210-B40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00421-010-1362-5","article-title":"Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients","volume":"109","author":"Hansen","year":"2010","journal-title":"Eur J Appl Physiol"},{"key":"2026081410521714900_xvag210-B41","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/oby.2010.193","article-title":"Effects of diabetes and obesity on vascular reactivity, inflammatory cytokines, and growth factors","volume":"19","author":"Doupis","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"2026081410521714900_xvag210-B42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12933-020-01028-1","article-title":"The additive effects of obesity on myocardial microcirculation in diabetic individuals: a cardiac magnetic resonance first-pass perfusion study","volume":"19","author":"Jiang","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2026081410521714900_xvag210-B43","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1161\/circulationaha.113.008476","article-title":"Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients","volume":"130","author":"Montaigne","year":"2014","journal-title":"Circulation"},{"key":"2026081410521714900_xvag210-B44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jacc.2016.03.597","article-title":"Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes","volume":"68","author":"Levelt","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026081410521714900_xvag210-B45","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/eurjpc\/zwad140","article-title":"Obesity in heart failure with preserved ejection fraction with and without diabetes: risk factor or innocent bystander?","volume":"30","author":"Prausm\u00fcller","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2026081410521714900_xvag210-B46","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026081410521714900_xvag210-B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.102185","article-title":"Epicardial adipose tissue, functional status, and invasive hemodynamics in heart failure with preserved ejection fraction","volume":"4","author":"Crum","year":"2025","journal-title":"JACC Adv"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag210\/70608580\/xvag210.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/4\/xvag210\/70608580\/xvag210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/4\/xvag210\/70608580\/xvag210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:29:21Z","timestamp":1786721361000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag210\/8758806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,11]]},"published-print":{"date-parts":[[2026,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag210","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,4]]},"article-number":"xvag210"}}